Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study

Abstract

Introduction An increasing number of studies are examining the link between the endocannabinoidome and major depressive disorder (MDD). We conducted an exploratory analysis of this system to identify potential markers of treatment outcomes.

Methods The dataset of the Canadian Biomarker Integration Network in Depression-1 study, consisting of 180 patients with MDD treated for eight weeks with escitalopram followed by eight weeks with escitalopram alone or augmented with aripiprazole was analyzed. Association between response Montgomery-Asberg Depression Rating Scale (MADRS; score reduction≥50%) or remission (MADRS score≤10) at weeks 8 and 16 and single nucleotide polymorphisms (SNPs), methylation, and mRNA levels of 33 endocannabinoid markers were examined. A standard genome-wide association studies protocol was used for identifying SNPs, and logistic regression was used to assess methylation and mRNA levels.

Results Lower methylation of CpG islands of the diacylglycerol lipase alpha gene (DAGLA) was associated with non-remission at week 16 (DAGLA; OR=0.337, p<0.003, q=0.050). Methylation of DAGLA was correlated with improvement in Clinical Global Impression (p=0.026), Quick Inventory of Depressive Symptomatology (p=0.010), and Snaith-Hamilton Pleasure scales (p=0.028). We did not find any association between SNPs or mRNA levels and treatment outcomes.

Discussion Methylation of DAGLA is a promising candidate as a marker of treatment outcomes for MDD and needs to be explored further.

Key words

endocannabinoid - major depressive disorder - methylation - DAGLA - antidepressant

• References

• 1 Friedrich MJ. Depression is the leading cause of disability around the world. JAMA 2017; 317: 1517
• 2 Rush AJ, Trivedi MH, Wisniewski SR. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917
• 3 Trivedi MH, Rush AJ, Wisniewski SR. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
• 4 Kennedy SH, Lam RW, McIntyre RS. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016; 61: 540-560
• 5 Joel I, Begley AE, Mulsant BH. et al. Dynamic prediction of treatment response in late-life depression. Am J Geriatr Psychiatry 2014; 22: 167-176
• 6 Karyotaki E, Smit Y, Holdt Henningsen K. et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. J Affect Disord 2016; 194: 144-152
• 7 Fitzgibbon KP, Plett D, Chan BCF. et al. Cost-utility analysis of electroconvulsive therapy and repetitive transcranial magnetic stimulation for treatment-resistant depression in Ontario. Can J Psychiatry 2020; 65: 164-173
• 8 Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005; 168: 299-325
• 9 Morena M, Patel S, Bains JS. et al. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 2016; 41: 80-102
• 10 Ibarra-Lecue I, Pilar-Cuéllar F, Muguruza C. et al. The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochem Pharmacol 2018; 157: 97-107
• 11 Navarrete F, Garcia-Gutierrez MS, Jurado-Barba R. et al. Endocannabinoid system components as potential biomarkers in psychiatry. Front Psychiatry 2020; 11: 315
• 12 Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 2020; 16: 9-29
• 13 Howlett AC, Barth F, Bonner TI. et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 2002; 54: 161-202
• 14 Di Marzo V, Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: ‘Killing two birds with one stone’. Prostaglandins Leukot Essent Fatty Acids 1995; 53: 1-11
• 15 Imperatore R, Morello G, Luongo L. et al. Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor CB(1)R signaling and anxiety-like behavior. J Neurochem 2015; 135: 799-813
• 16 Simon GM, Cravatt BF. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem 2008; 283: 9341-9349
• 17 Moreira FA, Crippa JA. The psychiatric side-effects of rimonabant. Braz J Psychiatry 2009; 31: 145-153
• 18 Martin M, Ledent C, Parmentier M. et al. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002; 159: 379-387
• 19 Hill MN, Miller GE, Ho WS. et al. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008; 41: 48-53
• 20 Hill MN, Ho WS, Hillard CJ. et al. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. J Neural Transm (Vienna) 2008; 115: 1673-1679
• 21 Smaga I, Bystrowska B, Gawlinski D. et al. Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. Neurotox Res 2014; 26: 190-206
• 22 Kranaster L, Hoyer C, Aksay SS. et al. Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: A preliminary prospective study. Eur Arch Psychiatry Clin Neurosci 2017; 267: 781-786
• 23 Kennedy SH, Lam RW, Rotzinger S. et al. Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjunctive aripiprazole therapy in patients with major depressive disorder: A CAN-BIND-1 Report. J Clin Psychiatry. 2019 80. 18m12202
• 24 Lam RW, Milev R, Rotzinger S. et al. Discovering biomarkers for antidepressant response: Protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry 2016; 16: 105
• 25 Yrondi A, Fiori LM, Frey BN. et al. Association between side effects and blood microRNA expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin reuptake inhibitor, Escitalopram: A CAN-BIND-1 Report. Int J Neuropsychopharmacol 2020; 23: 88-95
• 26 Marshe VS, Maciukiewicz M, Hauschild AC. et al. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Transl Psychiatry 2021; 11: 127
• 27 Ju C, Fiori LM, Belzeaux R. et al. Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. Transl Psychiatry 2019; 9: 254
• 28 Association AP. Diagnostic and Statistical Manual of Mental Disorders 4th Ed. Text Revision. ed. American Psychiatric Association; 2000
• 29 Sheehan DV, Lecrubier Y, Sheehan KH. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22-33 quiz 4-57
• 30 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
• 31 Purcell S, Neale B, Todd-Brown K. et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575
• 32 Maciukiewicz M, Marshe VS, Tiwari AK. et al. Genome-wide association studies of placebo and duloxetine response in major depressive disorder. Pharmacogenomics J 2018; 18: 406-412
• 33 Jeziorska DM, Murray RJS, De Gobbi M. et al. DNA methylation of intragenic CpG islands depends on their transcriptional activity during differentiation and disease. Proc Natl Acad Sci U S A 2017; 114: E7526-E7535
• 34 Affinito O, Palumbo D, Fierro A. et al. Nucleotide distance influences co-methylation between nearby CpG sites. Genomics 2020; 112: 144-150
• 35 Wang D, Yan L, Hu Q. et al. IMA: An R package for high-throughput analysis of Illumina’s 450K Infinium methylation data. Bioinformatics 2012; 28: 729-730
• 36 Akalin A, Kormaksson M, Li S. et al. methylKit: A comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol 2012; 13: R87
• 37 Starnawska A, Demontis D, McQuillin A. et al. Hypomethylation of FAM63B in bipolar disorder patients. Clin Epigenetics 2016; 8: 52
• 38 Middleton FA, Mirnics K, Pierri JN. et al. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 2002; 22: 2718-2729
• 39 Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration 1976
• 40 Spitzer RL, Kroenke K, Williams JB. et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092-1097
• 41 Szuhany KL, Young A, Mauro C. et al. Impact of sleep on complicated grief severity and outcomes. Depress Anxiety 2020; 37: 73-80
• 42 Yeung A, Feldman G, Pedrelli P. et al. The Quick Inventory of Depressive Symptomatology, clinician rated and self-report: A psychometric assessment in Chinese Americans with major depressive disorder. J Nerv Ment Dis 2012; 200: 712-715
• 43 Snaith RP, Hamilton M, Morley S. et al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167: 99-103
• 44 Greenwood CJ, Youssef GJ, Letcher P. et al. A comparison of penalised regression methods for informing the selection of predictive markers. PLoS One 2020; 15: e0242730
• 45 Trivedi MH, Papakostas GI, Jackson WC. et al. Implementing ,easurement-based care to determine and treat inadequate response. J Clin Psychiatry 2020; 81: OT19037BR1
• 46 Consortium B. Quantitative comparison of DNA methylation assays for biomarker development and clinical applications. Nat Biotechnol 2016; 34: 726-737
• 47 Starnawska A, Demontis D. Role of DNA methylation in mediating genetic risk of psychiatric disorders. Front Psychiatry 2021; 12: 596821
• 48 Jenniches I, Ternes S, Albayram O. et al. Anxiety, stress, and fear response in mice with reduced endocannabinoid levels. Biol Psychiatry 2016; 79: 858-868
• 49 Schuele LL, Glasmacher S, Gertsch J. et al. Diacylglycerol lipase alpha in astrocytes is involved in maternal care and affective behaviors. Glia 2021; 69: 377-391
• 50 Xue SS, Xue F, Ma QR. et al. Repetitive high-frequency transcranial magnetic stimulation reverses depressive-like behaviors and protein expression at hippocampal synapses in chronic unpredictable stress-treated rats by enhancing endocannabinoid signaling. Pharmacol Biochem Behav 2019; 184: 172738
• 51 Sheehan DV, Mancini M, Wang J. et al. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors. Hum Psychopharmacol 2016; 31: 53-63
• 52 Voineskos D, Blumberger DM, Rogasch NC. et al. Neurophysiological effects of repetitive transcranial magnetic stimulation (rTMS) in treatment resistant depression. Clin Neurophysiol 2021; 132: 2306-2316